{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03634540\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["belzutifan","cabozantinib"]],"indication":"advanced clear cell renal cell carcinoma","name":"LITESPARK-003","nct_id":"NCT03634540","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=litespark-003-nct03634540. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.","label":"Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)","type":"EXPERIMENTAL"},{"description":"Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.","label":"Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-02-26","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma (RCC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Kidney Cancer","Renal Cancer","Renal Cell Carcinoma","Renal Cell Cancer Metastatic","Renal Cell Carcinoma Recurrent","Renal Cell Cancer, Recurrent","Kidney"],"enrollment":{"count":118,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Belzutifan","otherNames":["PT2977, MK-6482","WELIREG™"],"type":"DRUG"},{"name":"Cabozantinib","otherNames":["CABOMETYX®"],"type":"DRUG"}],"last_update":"2024-12-20","lead_sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","official_title":"A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-02-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR)","timeFrame":"Up to approximately 2 years"}],"references":[{"citation":"Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D'Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31.","pmid":"37011650","type":"RESULT"},{"citation":"Choueiri TK, Merchan JR, Figlin R, McDermott DF, Arrowsmith E, Michaelson MD, Tykodi SS, Heath EI, Spigel DR, D'Souza A, Kassalow L, Perini RF, Vickery D, Bauer TM. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol. 2025 Jan;26(1):64-73. doi: 10.1016/S1470-2045(24)00649-1.","pmid":"39756444","type":"DERIVED"}],"start_date":{"date":"2018-09-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","url":"https://clinicaltrials.gov/study/NCT03634540"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/litespark-003-nct03634540"}